A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer

Simon P. Kim, Jon C Tilburt, Nilay D Shah, James B. Yu, Badrinath Konety, Paul L. Nguyen, Robert Abouassaly, Stephen B. Williams, Cary P. Gross

Research output: Contribution to journalArticle

Abstract

Background: Clinical factors and barriers affecting adoption of active surveillance (AS) for low-risk prostate cancer (PCa) remain poorly understood. We performed a national survey of radiation oncologists (RO) and urologists (URO) about the perceptions and recommendations of AS for low-risk PCa. Materials and Methods: In 2017, we surveyed 915 RO and 940 URO about AS for low-risk PCa in the United States. Survey items queried respondents about their attitudes toward AS and recommendations of AS for low-risk PCa. Pearson chi-square and multivariable logistic regression identified clinical and physician factors related toward AS for low-risk PCa. Results: Overall, the response rate was 37.3% (n = 691) and was similar for RO and URO (35.7% vs. 38.7%; P =.18). RO were less likely to consider AS effective for low-risk PCa (86.5% vs. 92.0%; P =.04) and more likely to rate higher patient anxiety on AS (49.5% vs. 29.5%; P <.001) than URO. Recommendations of AS varied modestly on the basis of age, prostate-specific antigen (PSA), and number of cores positive for Gleason 3 + 3 PCa. For a 55-year-old man with PSA 8 with 6 cores of Gleason 6 PCa, both RO and URO infrequently recommended AS (4.4% vs. 5.2%; adjusted odds ratio = 0.6; P =.28). For a 75-year-old patient with PSA 4 with 2 cores of Gleason 6 PCa, URO and RO most often recommended AS (89.6% vs. 83.4%; adjusted odds ratio = 0.5; P =.07). Conclusion: RO and URO consider AS to be effective in the clinical management of low-risk PCa, but this varies by clinical and physician factors. While active surveillance (AS) represents the preferred initial strategy for low-risk prostate cancer (PCa), understanding the barriers to its use is essential. In our national survey, recommendations of AS from case presentations varied by clinical factors and physician specialty. Fewer specialists recommended AS for younger age, higher prostate-specific antigen, or greater number of positive cores of Gleason 6 PCa.

Original languageEnglish (US)
JournalClinical Genitourinary Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Physicians
Radiation Oncologists
Urologists
Surveys and Questionnaires
Odds Ratio
Risk Management
Anxiety
Logistic Models

Keywords

  • Active surveillance
  • Physician bias
  • Prostate cancer
  • Survey

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. / Kim, Simon P.; Tilburt, Jon C; Shah, Nilay D; Yu, James B.; Konety, Badrinath; Nguyen, Paul L.; Abouassaly, Robert; Williams, Stephen B.; Gross, Cary P.

In: Clinical Genitourinary Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Kim, Simon P. ; Tilburt, Jon C ; Shah, Nilay D ; Yu, James B. ; Konety, Badrinath ; Nguyen, Paul L. ; Abouassaly, Robert ; Williams, Stephen B. ; Gross, Cary P. / A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. In: Clinical Genitourinary Cancer. 2019.
@article{d17de6b9c69e448a8ef33d480dde86a2,
title = "A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer",
abstract = "Background: Clinical factors and barriers affecting adoption of active surveillance (AS) for low-risk prostate cancer (PCa) remain poorly understood. We performed a national survey of radiation oncologists (RO) and urologists (URO) about the perceptions and recommendations of AS for low-risk PCa. Materials and Methods: In 2017, we surveyed 915 RO and 940 URO about AS for low-risk PCa in the United States. Survey items queried respondents about their attitudes toward AS and recommendations of AS for low-risk PCa. Pearson chi-square and multivariable logistic regression identified clinical and physician factors related toward AS for low-risk PCa. Results: Overall, the response rate was 37.3{\%} (n = 691) and was similar for RO and URO (35.7{\%} vs. 38.7{\%}; P =.18). RO were less likely to consider AS effective for low-risk PCa (86.5{\%} vs. 92.0{\%}; P =.04) and more likely to rate higher patient anxiety on AS (49.5{\%} vs. 29.5{\%}; P <.001) than URO. Recommendations of AS varied modestly on the basis of age, prostate-specific antigen (PSA), and number of cores positive for Gleason 3 + 3 PCa. For a 55-year-old man with PSA 8 with 6 cores of Gleason 6 PCa, both RO and URO infrequently recommended AS (4.4{\%} vs. 5.2{\%}; adjusted odds ratio = 0.6; P =.28). For a 75-year-old patient with PSA 4 with 2 cores of Gleason 6 PCa, URO and RO most often recommended AS (89.6{\%} vs. 83.4{\%}; adjusted odds ratio = 0.5; P =.07). Conclusion: RO and URO consider AS to be effective in the clinical management of low-risk PCa, but this varies by clinical and physician factors. While active surveillance (AS) represents the preferred initial strategy for low-risk prostate cancer (PCa), understanding the barriers to its use is essential. In our national survey, recommendations of AS from case presentations varied by clinical factors and physician specialty. Fewer specialists recommended AS for younger age, higher prostate-specific antigen, or greater number of positive cores of Gleason 6 PCa.",
keywords = "Active surveillance, Physician bias, Prostate cancer, Survey",
author = "Kim, {Simon P.} and Tilburt, {Jon C} and Shah, {Nilay D} and Yu, {James B.} and Badrinath Konety and Nguyen, {Paul L.} and Robert Abouassaly and Williams, {Stephen B.} and Gross, {Cary P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clgc.2019.01.008",
language = "English (US)",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",

}

TY - JOUR

T1 - A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer

AU - Kim, Simon P.

AU - Tilburt, Jon C

AU - Shah, Nilay D

AU - Yu, James B.

AU - Konety, Badrinath

AU - Nguyen, Paul L.

AU - Abouassaly, Robert

AU - Williams, Stephen B.

AU - Gross, Cary P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Clinical factors and barriers affecting adoption of active surveillance (AS) for low-risk prostate cancer (PCa) remain poorly understood. We performed a national survey of radiation oncologists (RO) and urologists (URO) about the perceptions and recommendations of AS for low-risk PCa. Materials and Methods: In 2017, we surveyed 915 RO and 940 URO about AS for low-risk PCa in the United States. Survey items queried respondents about their attitudes toward AS and recommendations of AS for low-risk PCa. Pearson chi-square and multivariable logistic regression identified clinical and physician factors related toward AS for low-risk PCa. Results: Overall, the response rate was 37.3% (n = 691) and was similar for RO and URO (35.7% vs. 38.7%; P =.18). RO were less likely to consider AS effective for low-risk PCa (86.5% vs. 92.0%; P =.04) and more likely to rate higher patient anxiety on AS (49.5% vs. 29.5%; P <.001) than URO. Recommendations of AS varied modestly on the basis of age, prostate-specific antigen (PSA), and number of cores positive for Gleason 3 + 3 PCa. For a 55-year-old man with PSA 8 with 6 cores of Gleason 6 PCa, both RO and URO infrequently recommended AS (4.4% vs. 5.2%; adjusted odds ratio = 0.6; P =.28). For a 75-year-old patient with PSA 4 with 2 cores of Gleason 6 PCa, URO and RO most often recommended AS (89.6% vs. 83.4%; adjusted odds ratio = 0.5; P =.07). Conclusion: RO and URO consider AS to be effective in the clinical management of low-risk PCa, but this varies by clinical and physician factors. While active surveillance (AS) represents the preferred initial strategy for low-risk prostate cancer (PCa), understanding the barriers to its use is essential. In our national survey, recommendations of AS from case presentations varied by clinical factors and physician specialty. Fewer specialists recommended AS for younger age, higher prostate-specific antigen, or greater number of positive cores of Gleason 6 PCa.

AB - Background: Clinical factors and barriers affecting adoption of active surveillance (AS) for low-risk prostate cancer (PCa) remain poorly understood. We performed a national survey of radiation oncologists (RO) and urologists (URO) about the perceptions and recommendations of AS for low-risk PCa. Materials and Methods: In 2017, we surveyed 915 RO and 940 URO about AS for low-risk PCa in the United States. Survey items queried respondents about their attitudes toward AS and recommendations of AS for low-risk PCa. Pearson chi-square and multivariable logistic regression identified clinical and physician factors related toward AS for low-risk PCa. Results: Overall, the response rate was 37.3% (n = 691) and was similar for RO and URO (35.7% vs. 38.7%; P =.18). RO were less likely to consider AS effective for low-risk PCa (86.5% vs. 92.0%; P =.04) and more likely to rate higher patient anxiety on AS (49.5% vs. 29.5%; P <.001) than URO. Recommendations of AS varied modestly on the basis of age, prostate-specific antigen (PSA), and number of cores positive for Gleason 3 + 3 PCa. For a 55-year-old man with PSA 8 with 6 cores of Gleason 6 PCa, both RO and URO infrequently recommended AS (4.4% vs. 5.2%; adjusted odds ratio = 0.6; P =.28). For a 75-year-old patient with PSA 4 with 2 cores of Gleason 6 PCa, URO and RO most often recommended AS (89.6% vs. 83.4%; adjusted odds ratio = 0.5; P =.07). Conclusion: RO and URO consider AS to be effective in the clinical management of low-risk PCa, but this varies by clinical and physician factors. While active surveillance (AS) represents the preferred initial strategy for low-risk prostate cancer (PCa), understanding the barriers to its use is essential. In our national survey, recommendations of AS from case presentations varied by clinical factors and physician specialty. Fewer specialists recommended AS for younger age, higher prostate-specific antigen, or greater number of positive cores of Gleason 6 PCa.

KW - Active surveillance

KW - Physician bias

KW - Prostate cancer

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=85062149203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062149203&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2019.01.008

DO - 10.1016/j.clgc.2019.01.008

M3 - Article

C2 - 30827923

AN - SCOPUS:85062149203

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

ER -